Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.
MacroGenics’ Cancer Drug Margenza Flops On Overall Survival Analysis
MacroGenics Inc (NASDAQ:MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a…